Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Lyme Disease Vaccine Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The lyme disease vaccine market has experienced substantial growth in recent years. Its value is projected to increase from $1.12 billion in 2025 to $1.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. This historical expansion can be attributed to the rising occurrence of lyme disease in endemic areas, the limitations of past antibiotic-only treatment approaches, early-stage initiatives in vaccine research, a growing public awareness of tick-borne infections, and improvements in public health surveillance.
The lyme disease vaccine market size is anticipated to undergo significant expansion in the upcoming years. It is predicted to reach $1.57 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.0%. This projected growth over the forecast period stems from the broader implementation of vaccination programs in endemic regions, increased investment in preventing infectious diseases, progress in next-generation vaccine platforms, a rise in the uptake of combination vaccines, and an intensified global concentration on controlling zoonotic diseases. Dominant trends during this period include advancements in recombinant vaccine technologies, a stronger emphasis on preventive immunization initiatives, an increase in clinical research for tick-borne diseases, a growing demand for long-lasting immunity solutions, and enhanced collaboration between public and private health organizations.
Get A Free Sample Report With In-Depth Market Insights:
Lyme Disease Vaccine Market Growth Backed By Core Demand Fundamentals
The rising incidence of Lyme disease is anticipated to boost the expansion of the Lyme disease vaccine market moving forward. Lyme disease, a tick-transmitted infection caused by Borrelia bacteria, can lead to symptoms such as fever, tiredness, skin rash, and potentially severe complications affecting joints, the heart, or the nervous system if not treated. The growth in Lyme disease cases is linked to climate change, as warmer weather and less severe winters extend tick living areas, leading to more human encounters with infected ticks. Lyme disease vaccines contribute to preventing the illness by preparing the immune system to identify and combat Borrelia bacteria, thereby lowering the chances of infection. These vaccines streamline disease management by offering enduring protection, which enhances overall public health outcomes. For example, in March 2025, the Centers for Disease Control and Prevention indicated that approximately 89,000 cases of Lyme disease were reported in the United States in 2023, while alternative estimations suggest that around 476,000 people might be diagnosed and treated for Lyme disease each year. Consequently, the increasing prevalence of Lyme disease is propelling the growth of the Lyme disease vaccine market.
Lyme Disease Vaccine Market Segment Landscape And Growth Outlook
The lyme disease vaccine market covered in this report is segmented –
1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types
2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test
3) By Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels
5) By End User: Hospitals, Clinical Laboratories, Other End Users
Subsegments:
1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines
2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines
3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines
4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines
Lyme Disease Vaccine Market Growth Trends Reshaping The Competitive Landscape
Leading companies in the Lyme disease vaccine market are concentrating on advancing their late-stage product candidates, such as booster vaccines, to address unmet medical needs, enhance immune protection, and simplify vaccination regimens. Booster vaccines are supplementary doses administered after the initial vaccination to restore or augment long-term immunity. For example, in September 2025, Valneva SE, a France-based biotechnology company, confirmed the positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine candidate, VLA15. This is a multivalent vaccine designed to train the immune system to produce antibodies against OspA proteins on Borrelia bacteria. When a tick bites, these antibodies block the bacteria inside the tick, preventing infection in humans. The robust immune response and favorable safety profile following a third booster dose were consistent with those reported after receiving prior annual booster doses, further demonstrating compatibility with the anticipated benefits of a yearly vaccination before each Lyme season. This booster strategy is designed to provide continuous protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for at-risk individuals.
Lyme Disease Vaccine Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.
View The Full Lyme Disease Vaccine Market Report:
Lyme Disease Vaccine Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model